uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience.
2005 (English)In: Neurological Research, ISSN 0161-6412, E-ISSN 1743-1328, Vol. 27, no 5, 516-521 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVES: The aim of the present study was to assess the usefulness of positron emission tomography (PET) with the amino acid tracer 11C-methionine (MET) as a predictor of time to progression (TTP) in patients with supratentorial grade 2 gliomas.

METHODS: Twenty-seven patients with glioma grade 2 subjected to a baseline PET scan received no anti-tumour treatment except for a diagnostic operation, and were followed until tumour progression. The prognostic impact of the MET uptake and of other prognostic factors was studied.

RESULTS: Twenty-five of the patients (93%) experienced tumour progression after a median of 103 weeks. Low uptake of MET was a predictor for long TTP in patients with oligodendrogliomas (p = 0.04) but not in astrocytomas/oligoastrocytomas. Other predictors for long TTP were oligodendroglioma histology (p = 0.009) and seizures as presenting symptom (p = 0.03). Favourable prognostic factors for overall survival were oligodendroglioma histology (p = 0.002) and good performance status (p = 0.03).

CONCLUSIONS: PET MET has a definite role in the therapeutic management of grade 2 gliomas. However, for the optimal use of PET MET in the clinical management of these patients, histological subclassification of the tumour is required.

Place, publisher, year, edition, pages
2005. Vol. 27, no 5, 516-521 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-219394DOI: 10.1179/174313213X13789811969265PubMedID: 15978178OAI: oai:DiVA.org:uu-219394DiVA: diva2:699659
Available from: 2014-02-28 Created: 2014-02-28 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Smits, Anja

Search in DiVA

By author/editor
Smits, Anja
By organisation
Department of Neuroscience
In the same journal
Neurological Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 615 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf